Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
telmisartan + metoprolol
- Development stage
- Unknown
- Lead developer
- Sanrey Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Teltsan M40/25 is a branded generic combination medication developed and marketed by Sanrey Therapeutics. It is formulated as an extended-release tablet containing 40 mg of telmisartan and 25 mg of metoprolol succinate. Telmisartan is an angiotensin II type 1 (AT1) receptor antagonist that promotes vasodilation and reduces aldosterone secretion, while metoprolol succinate is a cardioselective beta-1 adrenergic receptor blocker that decreases heart rate and cardiac contractility. The drug is indicated for the management of hypertension and the prevention of cardiovascular events such as myocardial infarction and stroke. It is administered orally once daily.
- Brand names
- Teltsan M40/25Teltsan M 40/25 Tablet ER
- Other names
- Teltsan M 40/25telmisartan/metoprolol succinate combination
02
Targets
ADRB1 (β1)PPARG (Peroxisome proliferator-activated receptor gamma)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on telmisartan + metoprolol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on telmisartan + metoprolol.